Labcorp Holdings (LH) Declares $0.72 Quarterly Dividend with 1.13% Yield
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: seekingalpha
- Quarterly Dividend Announcement: Labcorp Holdings has declared a quarterly dividend of $0.72 per share, consistent with previous distributions, indicating the company's stable cash flow and commitment to shareholder returns.
- Yield Information: The forward yield of this dividend stands at 1.13%, reflecting the company's attractiveness in the current market environment, which may draw in more income-focused investors.
- Shareholder Record Dates: The dividend is payable on March 12, with a record date of February 27 and an ex-dividend date also set for February 27, ensuring shareholders receive their payouts promptly.
- Future Outlook: Despite lowering the midpoint of its 2025 revenue guidance, Labcorp still targets an 8% revenue growth, demonstrating the company's ongoing efforts in restructuring and specialty expansion.
Analyst Views on LH
Wall Street analysts forecast LH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LH is 307.00 USD with a low forecast of 270.00 USD and a high forecast of 342.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 253.980
Low
270.00
Averages
307.00
High
342.00
Current: 253.980
Low
270.00
Averages
307.00
High
342.00
About LH
Labcorp Holdings Inc. provides comprehensive laboratory services that help doctors, hospitals, pharmaceutical companies, researchers and patients. The Company operates through two segments: Diagnostics Laboratories (Dx) and Biopharma Laboratory Services (BLS). The Diagnostics Laboratories segment includes routine testing and specialty/esoteric testing. Dx operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. The BLS segment provides drug development and CDx development solutions from early-stage research to clinical development, along with support for crop protection and chemical testing, through its ED and Central Laboratory Services businesses. Its service also includes ambulatory outpatient laboratory services. The Company is focused on four primary specialty testing areas, such as oncology, women's health, autoimmune disease, and neurology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
